About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker BDX · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026Evaluation of Catheter Utilization in Female Patients Using Indwelling Urinary Catheters and the Pu…
NCT07798128 · Urinary Incontinence, Limited Mobility
PureWick™ Flex Female External Catheter (FFEC), Indwelling…
BDX
Becton, Dickinson and Company
—Not yet recruiting240Jun 30, 2027Registry ↗
Oct 21, 2026This Study Will Collect Clinical and Patient Reported Satisfaction Data From Males Requiring Urine…
NCT06850259 · Urinary Incontinence
PureWick® Urine Collection System, UltraFlex™ Self-Adhering…
BDX
C. R. Bard
Not applicableCompleted15Jun 15, 2025Registry ↗
Oct 19, 2026Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
NCT03911700 · Open Midline Laparotomy
Phasix™ Mesh
BDX
C. R. Bard
Not applicableActive, not recruiting477Aug 2028Registry ↗
Oct 2, 2026Evaluation of Male and Female External Catheters for Urine Output Monitoring in the ICU
NCT07744945 · Urine Output, ICU Patients
Indwelling Urinary Catheter, External Urinary Catheter
BDX
C. R. Bard
—Enrolling by invitation32Oct 2026Registry ↗
Sep 25, 2026Study of GalaFLEX LITE™ Scaffold in Treatment of Capsular Contracture After Breast Implant Augmenta…
NCT05945329 · Capsular Contracture Associated With Breast Implant, Capsul…
GalaFLEX LITE™ Scaffold, Standard surgery
BDX
C. R. Bard
Not applicableRecruiting250Feb 2029Registry ↗
Aug 27, 2026The BD Liverty™ TIPS Stent Graft Study
NCT05711316 · Portal Hypertension, TIPS
BD Liverty™ TIPS Stent Graft
BDX
C. R. Bard
Not applicableActive, not recruiting177Jun 23, 2025Registry ↗
Aug 26, 2026HemoSphere Alta Study
NCT07148323 · Hemodynamic Instability
HemoSphere Alta Monitor, Swan-Ganz IQ pulmonary arterial ca…
BDX
Becton, Dickinson and Company
—Recruiting100Nov 2026Registry ↗
Aug 10, 2026Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
NCT04634916 · Kidney Disease, End-Stage, End-stage Renal Disease
EndoAVF Creation
BDX
C. R. Bard
Not applicableRecruiting220Jun 2027Registry ↗
Aug 4, 2026An Evaluation of the PureWick™ Male External Catheter Versus an Established Comparator Overnight in…
NCT07282860 · Urinary Incontinence
PureWick System, UltraFlex Self-Adhering Male External Cath…
BDX
C. R. Bard
Not applicableCompleted120Jun 22, 2026Registry ↗
Jul 13, 2026UK PureWick™ At-Home Pilot Study
NCT07555548 · Urinary Incontinence
Treatment with the PureWick™ Urine Collection System Extern…
BDX
Becton, Dickinson and Company
—Recruiting95Nov 2026Registry ↗
Jul 8, 2026ClearSight NextGen1 Study
NCT07317648 · Blood Pressure
ClearSight NextGen system
BDX
Becton, Dickinson and Company
Not applicableCompleted35Mar 5, 2026Registry ↗
Jul 8, 2026The Continuity Study
NCT07216573 · Blood Pressure
HemoSphere Vita Monitor with VitaWave or VitaWave Plus Fing…
BDX
Becton, Dickinson and Company
Not applicableRecruiting188Jan 2027Registry ↗
Jul 8, 2026Personal BP - CAI Study
NCT06492746 · Blood Pressure
HemoSphere Advanced Monitoring Platform with Acumen IQ sens…
BDX
Becton, Dickinson and Company
Not applicableRecruiting120Jan 2027Registry ↗
Jul 8, 2026SMART TRENDS Study
NCT05957406 · Moderate to High-risk Noncardiac Surgery
Acumen HPI Smart Alerts and Smart Trends Software, The Hemo…
BDX
Becton, Dickinson and Company
Not applicableCompleted296Oct 27, 2025Registry ↗
May 1, 2026Investigational Study With the BD PosiFlush™ SafeScrub on NADs
NCT06604026 · CRBSI - Catheter Related Bloodstream Infection
BD PosiFlush™ SafeScrub, BD PosiFlush™
BDX
Becton, Dickinson and Company
Not applicableCompleted222Apr 30, 2026Registry ↗
Mar 18, 2026Venclose digiRF System Post Market Study
NCT05504070 · Venous Reflux, Chronic Venous Insufficiency
Venclose System (digiRF generator w EVSRF catheter), Venclo…
BDX
C. R. Bard
Not applicableActive, not recruiting203Jul 17, 2025Registry ↗
Mar 18, 2026Post Approval Study Investigating Lutonix Drug Coated Balloon for Treatment of Dysfunctional Arteri…
NCT03506308 · Arteriovenous Fistula
LUTONIX 035 Drug Coated Balloon PTA Catheter
BDX
C. R. Bard
Not applicableActive, not recruiting213Apr 2027Registry ↗
Feb 10, 2026Observational Study of TissuePatch SF in Prevention of Air Leaks Following Lung Resection
NCT06934486 · Post-operative Air Leaks
TissuePatch Sealant Film
BDX
C. R. Bard
—Not yet recruiting250Feb 1, 2028Registry ↗
Jan 16, 2026BD Prevue(TM) II Peripheral Vascular Access System With Cue(TM) Needle Tracking Technology Clinical…
NCT06632496 · BD Prevue II for Peripheral Intravenous Catheter Placement
BD Prevue(TM) II
BDX
Becton, Dickinson and Company
—Completed156Sep 23, 2025Registry ↗
Jan 15, 2026BD SiteRite(TM) 9 Ultrasound System - Clinical Study
NCT06632509 · BD SiteRite 9 for VAD Insertion
BD SiteRite(TM) 9
BDX
Becton, Dickinson and Company
—Completed149Jan 9, 2026Registry ↗
Dec 22, 2025Study of BD Sirolimus Drug Coated Catheter for Treatment of Femoropopliteal Arteries
NCT05556681 · Peripheral Arterial Disease, Peripheral Artery Disease
BD™ Sirolimus Drug Coated Balloon Catheter percutaneous tra…
BDX
C. R. Bard
Not applicableCompleted34Jun 12, 2024Registry ↗
Dec 19, 2025Effectiveness and Safety of TIPS Stent Graft in the Treatment of Cirrhosis and Complications of Por…
NCT06669806 · Portal Hypertension Related to Cirrhosis, Ascites Hepatic
TIPS Stent Graft
BDX
C. R. Bard
Not applicableRecruiting166Jun 1, 2026Registry ↗
Dec 19, 2025Prospective Clinical Evaluation of BD NRFit™ Devices and Accessories.
NCT05953363 · Anesthesia, Analgesia
BD NRFit™ Spinal Needles, BD NRFit™ Spinal Introducer Needl…
BDX
Becton, Dickinson and Company
—Completed161May 28, 2024Registry ↗
Dec 17, 2025Real-World Registry of the Rotarex(TM) Rotational Excisional Atherectomy System (XTRACT Registry)
NCT07016698 · Peripheral Arterial Disease(PAD)
Rotarex(TM) Rotational Excisional Atherectomy System
BDX
C. R. Bard
Not applicableRecruiting600Mar 31, 2029Registry ↗
Dec 16, 2025Post Approval Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft
NCT04261686 · Arteriovenous Fistula
Covera Vascular Covered Stent
BDX
C. R. Bard
Not applicableCompleted100Sep 16, 2025Registry ↗
Dec 11, 2025everlinQ Endovascular Access System Enhancements (EASE) Study
NCT03708770 · Chronic Kidney Diseases
everlinQ endoAVF System
BDX
C. R. Bard
Not applicableCompleted32Jun 19, 2017Registry ↗
Dec 11, 2025everlinQ Endovascular Access Systems Enhancements (EASE-2) Study
NCT03708562 · Chronic Kidney Diseases
everlinQ endoAVF System
BDX
C. R. Bard
Not applicableCompleted24Dec 12, 2018Registry ↗
Dec 11, 2025Evaluating Safety and Effectiveness of Octenidine Dihydrochloride
NCT03140254 · Preoperative Skin Preparation
Chlorhexidine gluconate, N,N'-(1,10-decanediyldi-1(4H)-Pyri…
BDX
C. R. Bard
Phase 2Completed145Mar 17, 2017Registry ↗
Dec 11, 2025everlinQ endoAVF Post Market Study
NCT02682420 · Chronic Kidney Disease
everlinQ endoAVF System
BDX
C. R. Bard
Not applicableTerminated100Aug 2019Registry ↗
Dec 11, 2025Safety and Effectiveness of a New Pleural Catheter for Symptomatic, Recurrent, MPEs Versus Approved…
NCT02649894 · Malignant Pleural Effusion
Active Comparator: Approved Uncoated PleurX Indwelling Pleu…
BDX
C. R. Bard
Not applicableCompleted119Apr 18, 2018Registry ↗
Dec 11, 2025Topical Antimicrobial Effectiveness Testing
NCT01366417 · Antimicrobial Effectiveness
ChloraPrep One-Step, 70% isopropyl alcohol
BDX
C. R. Bard
Phase 4Completed25Jun 2011Registry ↗
Dec 11, 2025Topical Antimicrobial Effectiveness Testing
NCT01314703 · Antimicrobial Effectiveness
ChloraPrep One-Step, 70% isopropyl alcohol
BDX
C. R. Bard
Phase 4Completed27Apr 2011Registry ↗
Dec 11, 2025Test for Pre Operative Skin Preparations
NCT00799812 · Topical Antisepsis
CHG 2% w/v & IPA 70% v/v, swabstick (3 @ once)., CHG 2% w/v…
BDX
C. R. Bard
Phase 3Completed335Apr 27, 2008Registry ↗
Nov 26, 2025A Pilot Study Evaluating the Safety and Effectiveness of a New Pleural Catheter for the Medical Man…
NCT02227732 · Malignant Pleural Effusions
New Indwelling Pleural Catheter
BDX
C. R. Bard
Not applicableCompleted10May 2015Registry ↗
Nov 26, 2025A Prospective Clinical Evaluation of the Total Vascular Access (TVA) FLEX-1 Device Protocol FLEX-1-…
NCT02119845 · Chronic Kidney Disease (CKD)
Endovascular AVF (EndoAVF)
BDX
C. R. Bard
Not applicableCompleted16Apr 2013Registry ↗
Nov 26, 2025A Prospective Clinical Evaluation of the Total Vascular Access (TVA) FLEX-1 Device Protocol Flex-1-…
NCT02119832 · Chronic Kidney Disease (CKD)
Endovasccular AVF (EndoAVF)
BDX
C. R. Bard
Not applicableCompleted17Feb 2014Registry ↗
Nov 26, 2025Novel Endovascular Access Trial (NEAT)
NCT02036671 · Chronic Kidney Disease
The FLEX System will be used to percutaneously create a fis…
BDX
C. R. Bard
Not applicableCompleted80Dec 2015Registry ↗
Nov 26, 2025Components of Chlorhexidine Gluconate Dressing
NCT01112020 · Healthy
CHG Catheter Dressing Patch, Biopatch
BDX
C. R. Bard
Phase 1Completed45May 2010Registry ↗
Nov 26, 2025Pilot Evaluation of the Application Procedure on the Antimicrobial Effects of 2 Antiseptics
NCT00692484 · Healthy
Chlorhexidine gluconate, Povidone iodine
BDX
C. R. Bard
Phase 3Completed122Feb 2008Registry ↗
Nov 26, 2025Preoperative Skin Preparation Evaluation
NCT00636480 · Topical Antisepsis
Chlorhexidine gluconate, ChloraPrep One Step
BDX
C. R. Bard
Phase 3Completed60Mar 2008Registry ↗
Nov 20, 2025Clinical Validation of BACTEC™ Plus Aerobic/F Culture Vials Compared With Equivalent Product
NCT06426121 · Sepsis
test Aerobic/F Culture Vials, control Aerobic/F Culture Via…
BDX
Becton, Dickinson and Company
—Completed394Oct 23, 2025Registry ↗
Oct 20, 2025PureWick™ Adolescent Study
NCT06631313 · Healthy Volunteers, Adolescent
PureWick System
BDX
C. R. Bard
Not applicableCompleted43Sep 10, 2024Registry ↗
Jul 24, 2025This Study Will Collect Clinical and Patient Reported Experience Data From Participants Requiring U…
NCT06666426 · Adult Nocturnal Enuresis, Urinary Incontinence (UI)
PureWick System, Hollister Female Urinary Pouch External Co…
BDX
C. R. Bard
Not applicableCompleted171Jun 30, 2025Registry ↗
Jul 16, 2025PureWick™ France and U.S. At-Home Pilot Study
NCT05710718 · Nocturnal Enuresis
PureWick™ System, Hollister® Female Urinary Pouch External…
BDX
C. R. Bard
Not applicableCompleted17Aug 25, 2024Registry ↗
Jul 2, 2025Clinical Trial for Registration of HPV Nucleic Acid Genotyping Assay Kit
NCT04461678 · Cervical Cancer
HPV Genotyping Nucleic Acid Assay Kit
BDX
Becton, Dickinson and Company
Not applicableCompleted12,230Aug 26, 2024Registry ↗
Feb 3, 2025Investigational On-body Injector Clinical Study
NCT05553418 · Healthy Volunteers
In-clinic wear first, Home wear first
BDX
Becton, Dickinson and Company
Not applicableCompleted70Feb 8, 2023Registry ↗
Jan 27, 2025A Post-Market Clinical Follow Up Study to Evaluate BD PureHub™ Disinfecting Cap Use on Needle-Free…
NCT05130762 · Catheter Related Complication, Vascular Access Site Managem…
BD PureHub™ Disinfecting Cap Placements: Attachments/remova…
BDX
Becton, Dickinson and Company
Not applicableCompleted157May 22, 2023Registry ↗
Jan 16, 2025The WavelinQ™ Arterio-Venous Endovascular Fistula: A Global, Post-Market Investigation
NCT04626427 · End Stage Kidney Disease, Chronic Kidney Diseases
WavelinQ™ EndoAVF System
BDX
C. R. Bard
Not applicableTerminated21Jun 15, 2022Registry ↗
Sep 26, 2024BD OneFlow CLPD Panel (BD OneFlow LST, and B-CLPD T1 to T4 Assays) on the BD FACSLyric System.
NCT05557422 · Chronic Lymphoproliferative Diseases (CLPD)
BD OneFlow LST, and B-CLPD T1 to T4 Assays
BDX
Becton, Dickinson and Company
—Completed322May 8, 2024Registry ↗
Sep 19, 2024Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
NCT01231984 · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
4 mm x 32G Pen Needle, 8mm x 31G Pen Needle
BDX
Becton, Dickinson and Company
Not applicableCompleted293May 2012Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:07 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances